Improving Patients’ Lives Through Novel Cancer Therapeutics
Bantam is developing small molecule drugs that target a critical nexus involving cancer cell metabolism, cell cycle control, and oncogenic protein synthesis.
Dysregulated metabolism and cell cycle control are hallmarks of hematological malignancies and solid tumors; and notably in aggressive, drug resistant cancers with few or no treatment options.
Our current clinical focus is on biologically defined niches of unmet need in relapsed and refractory cancers.
Current Proof of Concept clinical studies are focused on B-cell lymphoma with the intent of filing for Orphan Drug Indications.